tained as ascites-monoclonal antibody 10-3.6 in BALB/c mice and BP107 in (SJL X BALB/c) mice. Both monoclonal antibodies had binding titers >103 on appropriate spleen cells.
Immunizations. In some experiments, soluble AcChoR was administered (50 pg in phosphate-buffered saline) in 500 ,ul intraperitoneally at 1-week intervals. To investigate anti-AcChoR antibody levels after administration of AcChoR in adjuvant and to induce clinical EAMG (2), emulsified AcChoR, 15 /kg in complete Freund adjuvant (Difco), was injected intradermally among six sites on the back, the hind foot pads, and the base of the tail. Animals were reimmunized with this same regimen 4 weeks later (2) . For lymphocyte proliferation experiments, mice were immunized in the hind foot pads with 7.5 pLg of AcChoR emulsified in complete Freund's adjuvant containing mycobacterium H37Ra (400 Ag/ml) in a volume of 100 A1.
Enzyme-linked Immunoadsorbent Assay (ELISA) for AntiAcChoR Antibody. A microtiter ELISA was developed to measure the anti-AcChoR antibody levels (9) . A standard reagent volume of 50 ,ul per microtiter well was always used. Unless otherwise specified, reagents were incubated in the wells for 2 hr at room temperature. Five micrograms of AcChoR diluted in bicarbonate buffer (pH 9.6) was added to each well of Immulon (Dynatech Laboratories, Alexandria, VA) microtiter plates. After incubation with the AcChoR, the plates were rinsed four times with a wash solution consisting of phosphate-buffered saline containing 0.05% Tween (polyoxethylene-20 sorbitan monooleate) and 0.05% NaN3. It was determined experimentally that 5 ug of AcChoR per microtiter well was in excess of the amount of AcChoR needed to bind all of the anti-AcChoR antibody in a standard anti-AcChoR antiserum (defined below). Mouse sera were diluted in 0.01 M phosphate-buffered saline, pH 7.2/1.5 mM MgCl2/2.0 mM 2-mercaptoethanol/.05% Tween-80/0.05% NaN3 (P04-Tween buffer) and incubated on the plate. After the plate was washed, ,B-galactosidase-conjugated sheep anti-mouse antibody [(Fab)2; Bethesda Research Laboratory] diluted 1:100 in P04-Tween buffer was added to each well. After a final washing, the enzyme substrate p-nitrophenyl-,BD-galactopyranoside at 1 mg/ml was added to the plate and the degree of substrate catalysis was determined from the absorbance at 405 nm after 1 hr, measured in an automated spectrophotometer.
In each assay, a standard antiserum was serially diluted and a plot of volume of standard antiserum versus absorbance was made. All test antisera were always diluted so that they were in the linear part of this standard curve. Pooled serum from SJL/J mice (bled 8 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Lymphocyte Proliferation. Seven days after immunization, mice were sacrificed and the popliteal lymph nodes were removed. Lymph node cells were dissociated in phosphate-buffered saline, washed three times, and resuspended in culture medium RPMI 1640 (GIBCO), supplemented with penicillin G (100 units/ml), streptomycin (100 ,ug/ml), 2-mercaptoethanol (30 MLM), and 2% heat-inactivated horse serum. Cells (5 x 105) were cultured for 5 days in flat-bottomed Costar (Cambridge, MA) microtiter plates at 370C in a humidified 5% C02/95% air environment. AcChoR protein (0.5 ug per well) and purified protein derivative (16 after immunization. Administration of anti-I-A was repeated at the time of the secondary immunization. Animals were bled 1 week after secondary immunization, and titers were determined with an ELISA for anti-AcChoR antibody.
In the susceptible SJL/J (H-2S) mouse, three groups were studied: group 1 received no monoclonal antibody, group 2 received monoclonal anti-I-Ab which does not bind to SJL/J cells, and group 3 received anti-I-A'. After secondary intraperitoneal immunization of SJL/J mice with soluble AcChoR, anti-AcChoR titers were decreased by anti-I-A' treatment, compared to treatment with the noncrossreactive anti-I-Ab or no monoclonal antibody. After secondary immunization (Fig. 1 .Left) , mean (±SD) anti-AcChoR antibody was 22.3 ± 5.9 X 10-3 ul with no treatment, 18.6 ± 17.7 x 10-3 ,l with anti-I-A1, and 0.2 ± 0.4 X 10-3 ,l with anti-I-As (P < 0.0001 for I-As vs. no monoclonal and P < 0.02 for I-As vs. I-Ab). Similar results were obtained in three subsequent experiments. Thus it appears that, in vivo, treatment with anti-I-A antibody almost entirely prevents an antibody response to soluble AcChoR.
To test the ability of the anti-I-Ab monoclonal antibody (BP 107) to decrease anti-AcChoR antibody titers, C57BL/Ka (C57BL/6) (H-2b) mice, which are also susceptible to EAMG (2, 10), were used. After primary and secondary immunization of these mice with 50 ,ug of soluble AcChoR intraperitoneally ( After primary and secondary immunizations of SJL/J mice with 15 ,g of AcChoR in complete Freund adjuvant (Fig. 2) , antibody titers were 14.3 ± 4.9 X 10-1 1.l in the no-treatment group, 14.1 ± 4.7 X 10-l in the anti-I-Ab antibody group, and 9.0 ± 4.0 x 10-1 p1 in the anti-I-A' antibody group (P < 0.01 for anti-I-A' compared to no monoclonal or anti-I-Ab treatment). Similar results were obtained in a second experiment with 10 (10) . Weakness was ameliorated (unless mice were moribund) within 5-10 min of administration of neostigmine bromide (0.0375 mg/kg) and atropine sulfate (0.015 mg/kg) intraperitoneally. Clinical disease was ap parent in 11 of 19 control animals (7 of 9 treated with anti-I-A and 4 of 10 untreated); 2 of 10 anti-I-A'-treated animals were mildly myasthenic (X2 Wfi continuity correction = 4.28, P< T.03Tfor antf-I-Ab vs. anti-I-A' treatment; x2 with continuity correction = 2.48, P < 0.12 for both control groups vs. the anti-I-A'-treated group).
DISCUSSION
These experiments indicate that in vivo therapy with monoclonal antibody to I-A gene products partially suppresses both cellular and humoral responses to AcChoR and appears to suppress clinical EAMG. The decrease in anti-AcChoR titers observed with in vivo anti-I-A therapy is greater than that achieved with other experimental therapies for myasthenia gravis such as cyclophosphamide and bone marrow transplantation in rats (11) or plasmapheresis and azathioprine in humans (12, 13) . The present experiments with anti-I-A antibody treatment revealed a 40% reduction of anti-AcChoR antibody titers after a severe challenge with AcChoR in complete Freund adjuvant, injected at multiple sites to induce disease. It is clear, however, that anti-I-A antibody can prevent an anti-AcChoR antibody response almost completely after soluble immunization, a condition perhaps resembling natural autoimmunization more closely.
These results extend earlier observations on the influence of anti-I-A antibodies in vivo. These effects include prolonged graft survival (14) , regulation of immunity to tumors (15, 16) , inhibition of schistosome granuloma formation (17) , potentiation of antibody responses (18) , and inhibition of T-helper cell induction (19) . More recently, haplotype-specific suppression of antibody responses to antigens under Ir gene control (4), and prevention of clinical EAE (5) have been accomplished with monoclonal anti-I-A antibody.
Therapy with monoclonal anti-I-A', unlike other current therapies for myasthenia gravis, had some antigenic specificity. Whereas cellular proliferation responses to AcChoR-an antigen clearly under Ir gene control (1-3)-were decreased, the responses to purified protein derivative-which is not under Ir gene control-were in the I-AS-treated animals not significantly different from those in the untreated animals. It is not clear why the response to purified protein derivative is not at least partially suppressed. No diminution in the purified protein derivative response after anti-I-A treatment has been observed in EAE as well (unpublished data).
As other investigators have observed (20) (21) (22) (23) . Another possibility, not mutually exclusive, is that treatment with anti-I-A activates suppressor cells for AcChoR. Administration of anti-I-A both in vitro and in vivo has been shown to induce suppressor cells in various systems (24) (25) (26) . A suppressor T cell for anti-AcChoR antibody responses is induced after anti-I-A treatment in vivo (unpublished data).
Myasthenia gravis is one of several human autoimmune diseases linked to HLA-D (27, 28) . In myasthenia gravis, antibodies to AcChoR impair neuromuscular transmission by mediating loss of AcChoR in the postsynaptic membrane (29, 30 
